Alnylam has advanced its investigational RNAi candidate, ALN-4324, into a Phase 2 clinical trial, having initiated the study in March 2026. The randomized, double-blind, placebo-controlled study will evaluate the effect of a single subcutaneous injection on whole-body insulin sensitivity in adults with Type 2 diabetes.
The company describes ALN-4324 as an investigational RNAi therapeutic targeting GRB14, a potential insulin sensitizer. The trial’s registration and protocol materials outline the study design and objectives for measuring insulin sensitivity following a single dose.
Alnylam, founded in 2002 and based in Massachusetts, is expanding its pipeline into metabolic disease alongside its established RNAi development programs.
